Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

De.mem Limited

ABN

12 614 756 642

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Fully paid ordinary shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

4,587,762

Fully paid ordinary shares

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next</li> </ul>	
	dividend, distribution or interest payment	
5	Issue price or consideration	\$0.135 per share
-		
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Non-renounceable Entitlements issue pursuant to the offer document dated 26 November 2018
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The data the accurity helder	an Mary and
OD	The date the security holder resolution under rule 7.1A was passed	29 May 2018
6-	Number of the subtract is 1	NT'1
6с	Number of <i>*</i> securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued	Nil

under rule 7.1A

with security holder approval

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the \*issue date and both values. Include the source of the VWAP calculation.
- 6h If \*securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 <sup>+</sup>Issue dates
- 8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the <sup>+</sup>securities in section 2 if applicable)

Number	+Class
112,256,736	Ordinary fully paid shares, including:-
	58,655,882 Ordinary fully paid shares, subject to ASX restriction to 7 April 2019
	7,840,843 shares subject to voluntary escrow to 7 April 2019
	1 (41110)01

4,587,762 fully paid ordinary shares

N/A

N/A

Nil

.

Refer annexure

24 December 2018

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX ( <i>including</i> the <sup>+</sup> securities in section 2 if applicable)	3,800,000	Unlisted options, exercisable at \$0.30 each, expiring on or before 30 March 2020, subject to ASX restriction to 7 April 2019
		4,250,000	Unlisted options, exercisable at \$0.30 each, expiring on or before 21 November 2019, subject to ASX restriction to 7 April 2019
		375,000	Unlisted options, exercisable at \$0.30 each, on or before 15 May 2020, vesting two years from the date of issue, subject to continued and unterminated service to the Company
		375,000	Unlisted options exercisable at \$0.30 each, on or before 15 May 2020, vesting two weeks before the anniversary of three years from the date of issue, subject to continued and unterminated service to the Company
		1,250,000	Unlisted options exercisable at \$0.30 each, on or before 11 September 2020
		250,000	Unlisted options exercisable at \$0.30 on or before 13/04/2021 vesting 13/04/2020, subject to continued and unterminated service to the Company.
		250,000	Unlisted options exercisable at \$0.30 on or before 10/04/2021 vesting 31/03/2021, subject to continued and unterminated service to the Company.
10	Dividend policy (in the case of a trust, distribution policy) on the	N/A	

+ See chapter 19 for defined terms.

increased capital (interests)

# Part 2 - Pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-renounceable?	Non-renounceable
13	Ratio in which the <sup>+</sup> securities will be offered	1 for 7
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Fully paid ordinary shares
15	<sup>+</sup> Record date to determine entitlements	29 November 2018
16	Will holdings on different	N/A
	registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	Fractional entitlements will be rounded up to the nearest whole number
18	Names of countries in which the entity has security holders who will not be sent new offer documents	Countries other than in Australia, New Zealand, Singapore, Hong Kong, Germany and Switzerland
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	17 December 2018

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	4 December 2018
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	27 November 2018
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Issue date

N/A

24 December 2018

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of <sup>+</sup>securities (*tick one*)
- (a)

<sup>+</sup>Securities described in Part 1

(b)

All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

10,001 - 100,000 100,001 and over

35

37

- If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders
- 36 If the \*securities are \*equity securities, a distribution schedule of the additional \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000

A copy of any trust deed for the additional +securities

<sup>+</sup> See chapter 19 for defined terms.

Entities that have ticked box 34(b)		
Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought	N/A	
<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?	N/A	
<ul> <li>If the additional *securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another <sup>+</sup> security, clearly identify that other <sup>+</sup> security)	N/A	
	Number	<sup>+</sup> Class
Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	N/A	N/A
	<ul> <li>Number of *securities for which *quotation is sought</li> <li>*Class of *securities for which quotation is sought</li> <li>Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?</li> <li>If the additional *securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> <li>Reason for request for quotation now</li> <li>Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)</li> <li>Number and *class of all *securities in clause</li> </ul>	Number of *securities for which *quotation is sought       N/A         *Class of *securities for which quotation is sought       N/A         Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?       N/A         If the additional *securities do not rank equally, please state:       N/A         • the date from which they do       • the extent to which they do         • the extent to which they do       • the extent to which they do         • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment       N/A         Reason for request for quotation now       N/A         Example In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)       N/A         Number       Number         Number and *class of all *securities quoted on ASX (including the *securities in clause       N/A

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

(Company secretary)

**Brett Tucker** 

Date: 24 December 2018

Sign here:

Print name:

== == == == =

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>		
<ul> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	1,807,200 – Akwa Worx vendor shares (issued on 18 September 2017)	
	9,433,962 – Placement to Institutional investors from Australia, Germany and Singapore	
	620,120 – Akwa Worx deferred consideration shares for meeting Milestone 1 (issued on 20 February 2018)	
<ul> <li>Number of partly paid <sup>+</sup>ordinary securities that became fully paid in that 12 month period</li> </ul>	4,587,762 – Non-renounceable Rights Issue	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of provide an different determined</li> </ul>		
securities on different dates as separate line items Subtract the number of fully paid <sup>+</sup> ordinary	Nil	
securities cancelled during that 12 month period		
"A"	112,256,736	

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	16,838,510	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	-	
• Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	-	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	16,838,510	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	16,838,510	

[Note: this is the remaining placement

capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

# Part 2 – Not Applicable

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	11,225,674	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	-	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	11,225,674	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	11,225,674	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.